Dosage effects of riluzole in Huntington's disease: A multicenter placebo-controlled study

Neurology

Volumn 61, Issue 11, 2003, Pages 1551-1556

  Marshall, F J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PLACEBO; RILUZOLE;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; BEHAVIOR; CHOREA; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RELEASE; FATIGUE; HUMAN; HUNTINGTON CHOREA; MOTOR ACTIVITY; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; UNIFIED HUNTINGTON DISEASE RATING SCALE; URINE INCONTINENCE; VERTIGO; WEIGHT REDUCTION;

EID: 0345600893     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000096019.71649.2b     Document Type: Article

References (39)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Paulson HL, Fischbeck KH. Trinucleotide repeats in neurogenetic disorders. Annu Rev Neurosci 1996;19:79-107.
3. Marshall FJ, Shoulson I. Huntington's disease: clinical features and therapy. In: Watts RL, Koller WC, eds. Movement disorders: neurologic principles and practice. New York: McGraw-Hill, 1997:491-502.
4. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-577.
5. Harper PS. The epidemiology of Huntington's disease. Hum Genet 1992;89:365-376.
6. Tanner CM, Goldman SM. Epidemiology of movement disorders. Curr Opin Neurol 1994;7:325-332.
7. Cheramy A, Barbeito L, Godeheu G, Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 1992;147:209-212.
8. Debono MW, LeGuern J, Canton T, et al. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993;235:283-289.
9. Malgouris C, Daniel M, Doble A. Neuroprotective effects of riluzole on N-methyl-D-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices. Eur J Pharmacol 1994;177:95-99.
10. Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibers. Pflugers Arch 1991;419:603-609.
11. Schwarcz R, Whetsell WO, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1982;219:316-318.
12. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986;321:168-171.
13. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 1991;11:1649-1659.
14. Mary V, Wahl F, Stutzmann JM. Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission. Neurosci Lett 1995;201:92-96.
15. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histological characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993;13:4181-4192.
16. Guyot MC, Palfi S, Stutzmann JM, Maziere M, Hantraye P, Brouillet E. Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience 1997;81:141-149.
17. Brouillet E, Hantraye P, Ferrante RJ, et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 1995;92:7105-7109.
18. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri MC. 3-Nitropropionic acid: exogenous neurotoxin and possible human striatal toxin. Can J Neurol Sci 1991;18:377-393.
19. Palfi S, Riche D, Brouillet E, et al. Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. Exp Neurol 1997;146:135-141.
20. Rosas HD, Koroshetz WJ, Jenkins BG, et al. Riluzole therapy in Huntington's disease (HD). Mov Disord 1999;14:326-330.
21. Seppi K, Mueller J, Bodner T, et al. Riluzole in Huntington's disease (HD): an open label study with one year follow up. J Neurol 2001;248:866-869.
22. Shoulson I, Fahn S. Huntington's disease: clinical care and evaluation. Neurology 1979;29:1-3.
23. Shoulson I, Kurian R, Rubin AJ, et al. Assessment of functional capacity in neurodegenerative movement disorders: Huntington's disease as a prototype. In: Munsat TL, ed. Quantification of neurological deficit. Boston: Butterworths, 1989:271-283.
24. Kieburtz K, Feigin A, McDermott M, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 1996;11:272-277.
25. Huntington Study Group. Unified Huntington's Disease Rating Scale. Reliability and consistency. Mov Disord 1996;11:136-142.
26. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Neurology 2000;54:452-458.
27. Smith A. Symbol Digit Modalities Test Manual. Los Angeles: Western Psychological Services, 1973.
28. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643-662.
29. Benton AL, Hamsher KD. Multilingual Aphasia Examination Manual. Iowa City: University of Iowa, 1978.
30. Huntington Study Group. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. Neurology 1998;50:1366-1373.
31. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612.
32. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.
33. Kremer B, Clark CM, Almqvist EW, et al. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 1999;53:1000-1011.
34. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.
35. Verhagen L, Morris M, Farmer C, Gillespie M, Wuu J, Chase TN. A double-blind, placebo-controlled crossover study of the effect of amantadine on chorea in Huntington's disease. Neurology 2001;56(suppl 3): A386.
36. Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of baclofen in Huntington's disease. Ann Neurol 1989;25:252-259.
37. Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
38. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, ALS/ Riluzole Study Group. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
39. Physicians' desk reference. 57th ed. Montvale, NJ: Thompson PDR, 2003:767-769.